40T Stock Overview
An investment holding company, provides medical care, consultancy, treatment, and surgery services in the field of ophthalmology in Singapore, Malaysia, and Myanmar.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
ISEC Healthcare Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | S$0.38 |
| 52 Week High | S$0.48 |
| 52 Week Low | S$0.25 |
| Beta | 0.13 |
| 11 Month Change | 0% |
| 3 Month Change | -6.25% |
| 1 Year Change | -7.41% |
| 33 Year Change | 22.95% |
| 5 Year Change | 5.63% |
| Change since IPO | 1.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| 40T | SG Healthcare | SG Market | |
|---|---|---|---|
| 7D | -2.6% | 0.7% | 2.3% |
| 1Y | -7.4% | -17.7% | 9.9% |
Return vs Industry: 40T exceeded the SG Healthcare industry which returned -17.7% over the past year.
Return vs Market: 40T underperformed the SG Market which returned 9.9% over the past year.
Price Volatility
| 40T volatility | |
|---|---|
| 40T Average Weekly Movement | n/a |
| Healthcare Industry Average Movement | 7.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in SG Market | 16.1% |
| 10% least volatile stocks in SG Market | 2.5% |
Stable Share Price: 40T has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine 40T's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | n/a | Jun Shyan Wong | www.isechealthcare.com |
ISEC Healthcare Ltd., an investment holding company, provides medical care, consultancy, treatment, and surgery services in the field of ophthalmology in Singapore, Malaysia, and Myanmar. The company operates through two segments, Specialised Health Services and General Health Services. It offers a range of eye care services, including cataract and intraocular lens implant surgeries; refractive surgeries; vitreous and retinal diseases; cornea, external eye disease, and anterior surgeries; adult strabismus and paediatric ophthalmology, glaucoma diagnostics and therapeutics, medical retinal diseases, uveitis, oculoplastics, facial cosmetics, and aesthetics surgeries, as well as optometry and orthoptics.
ISEC Healthcare Ltd. Fundamentals Summary
| 40T fundamental statistics | |
|---|---|
| Market cap | S$215.70m |
| Earnings (TTM) | S$13.40m |
| Revenue (TTM) | S$70.98m |
16.1x
P/E Ratio3.0x
P/S RatioIs 40T overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 40T income statement (TTM) | |
|---|---|
| Revenue | S$70.98m |
| Cost of Revenue | S$39.55m |
| Gross Profit | S$31.43m |
| Other Expenses | S$18.04m |
| Earnings | S$13.40m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.023 |
| Gross Margin | 44.28% |
| Net Profit Margin | 18.87% |
| Debt/Equity Ratio | 2.1% |
How did 40T perform over the long term?
See historical performance and comparison